This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FSDC vs. FOLD, XENE, MLTX, BHC, BHVN, MIRM, GMTX, BLTE, NAMS, and LGNDShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Bausch Health Companies (BHC), Biohaven (BHVN), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), and Ligand Pharmaceuticals (LGND). These companies are all part of the "medical" sector. FS Development vs. Amicus Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics Bausch Health Companies Biohaven Mirum Pharmaceuticals Gemini Therapeutics Belite Bio NewAmsterdam Pharma Ligand Pharmaceuticals Amicus Therapeutics (NASDAQ:FOLD) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings. Does the MarketBeat Community prefer FOLD or FSDC? Amicus Therapeutics received 532 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% FS DevelopmentN/AN/A Does the media favor FOLD or FSDC? In the previous week, Amicus Therapeutics had 9 more articles in the media than FS Development. MarketBeat recorded 9 mentions for Amicus Therapeutics and 0 mentions for FS Development. Amicus Therapeutics' average media sentiment score of 0.81 beat FS Development's score of 0.00 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Amicus Therapeutics Positive FS Development Neutral Which has better valuation and earnings, FOLD or FSDC? FS Development has lower revenue, but higher earnings than Amicus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.30M4.65-$151.58M-$0.18-44.44FS DevelopmentN/AN/AN/AN/AN/A Is FOLD or FSDC more profitable? FS Development has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -10.62%. Amicus Therapeutics' return on equity of 12.44% beat FS Development's return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-10.62% 12.44% 2.60% FS Development N/A N/A N/A Do analysts rate FOLD or FSDC? Amicus Therapeutics currently has a consensus target price of $16.75, suggesting a potential upside of 109.38%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in FOLD or FSDC? 89.8% of FS Development shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAmicus Therapeutics beats FS Development on 10 of the 12 factors compared between the two stocks. Remove Ads Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$607.40M$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E RatioN/A6.9923.2518.07Price / SalesN/A198.60361.2686.83Price / CashN/A65.6738.1634.64Price / BookN/A5.926.493.99Net IncomeN/A$142.37M$3.21B$247.18M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$48.53+2.9%N/A+47.2%$607.40MN/A0.00N/ANews CoverageFOLDAmicus Therapeutics4.1519 of 5 stars$8.08-1.0%$16.75+107.4%-29.7%$2.48B$528.30M-44.92480Analyst RevisionNews CoverageGap DownXENEXenon Pharmaceuticals2.3579 of 5 stars$32.11-4.3%$57.38+78.7%-24.1%$2.46B$9.43M-11.40210Options VolumeNews CoverageGap DownMLTXMoonLake Immunotherapeutics2.0467 of 5 stars$38.12-2.4%$80.50+111.2%-19.5%$2.44BN/A-29.562News CoveragePositive NewsBHCBausch Health Companies4.2901 of 5 stars$6.40-1.2%$7.42+16.0%-40.0%$2.36B$9.63B-53.3719,900News CoverageBHVNBiohaven3.8675 of 5 stars$22.62-5.9%$62.77+177.5%-53.4%$2.31BN/A-2.43239Gap DownMIRMMirum Pharmaceuticals4.3193 of 5 stars$44.11-2.1%$58.20+31.9%+78.5%$2.16B$336.89M-21.86140Positive NewsGMTXGemini TherapeuticsN/A$49.64-5.2%N/A+37.8%$2.15BN/A-49.6430Positive NewsHigh Trading VolumeBLTEBelite Bio1.974 of 5 stars$65.42-1.2%$96.67+47.8%+71.3%$2.08BN/A-58.9410NAMSNewAmsterdam Pharma2.5181 of 5 stars$18.91-7.6%$43.33+129.2%-14.9%$2.07B$45.56M-7.244News CoverageGap DownLGNDLigand Pharmaceuticals4.3273 of 5 stars$106.05+0.9%$147.00+38.6%+48.5%$2.04B$167.13M42.3180Short Interest ↑Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Amicus Therapeutics Competitors Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Bausch Health Companies Competitors Biohaven Competitors Mirum Pharmaceuticals Competitors Gemini Therapeutics Competitors Belite Bio Competitors NewAmsterdam Pharma Competitors Ligand Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
